While mechanisms of IFN-γ-induced JAK1/JAK2-STAT1 signaling have been extensively reviewed elsewhere [54,55], JAK inhibition has been successfully used in treating cutaneous sarcoidosis [27,35,56]. The gene discussed is STAT1; the disease is skin sarcoidosis.